Healthtech Days #2 2021

PROGRAM
13th October – Day 1

EU market access strategy for health products and country particularities

OPENING PLENARY SESSIONS: 14:00 – 14:15

THEMATIC WORKSHOP SESSIONS: 14:15 – 15:15

14:00 –14:15 Opening remarks
Speakers:
Dr. Thomas Scheuerle, Managing Director at BadenCampus
Dr. Guillaume Vetter-Genoud, Head of deeptech/healthcare, SEMIA
Maarten van Winckel, Startup Community & Initiatives at University
of Basel
Bodo Brückner, Startup Advisor; Coordinator Lifescience Accelerator
Baden-Wuerttemberg
Markus Bühler, Coordinator Lifescience Accelerator Baden-
Wuerttemberg

14:15 – 15:00 Session A (for Digital health/Medtech Startups)
How to access clinics as a startup?
From the 1st experimentations until the clinical trials.
This session will shed some light on how startup teams can get access to hospitals. To this end the speakers will present different approaches and strategies ranging from consultancy services to whole clinical departments including patient, nurses and doctors interacting with teams.
Moderator: Bodo Brückner
Speakers:
Annegret Genger, Senior Consultant Regulatory and Clinical Affairs at
Seleon
Mirjam Schleske, Organisational Management INSPIRE Living Lab
Dr. Christian Haverkamp, Acting Director, “Institut für Digitalisierung
in der Medizin” at Uniklinik Freiburg
Matis Ringdal, CEO at Pixacare
Olivier Terenzi, Clinical research project manager at OMEOS

15:00 –15:15 Q&A

14:15 –15:00 Session B (for Biotech Startups)

When and how to start discussing with major corporates / big pharma as Start up?
This session will, in a very open manner, address topics relevant for
start-ups wanting to collaborate with corporates / big pharma. What do you need to consider to maximize your chances for collaboration and when is the best time in your journey to think about this endeavor, are just a few of the questions that will be addressed during this session.
Moderator: Maarten Van Winckel
Speakers:
Samantha Brandler, Head of Research Innovation, Europe at CSL
Behring
Michael R Huebner, Director Early Innovation Partnering at Johnson
and Johnson
Ashley Nagle, Vice President of Business Development at RemedyBio
Jonathan Butcher, Head of Business Development and Alliance
Management at BioVersys

15:00 – 15:15 Q&A

GENERAL TALK: 15:25 – 16:25

15:25 –16:10 Successful access and cooperation
How does the successful acquisition of a signi􀀂cant investment work, what are the main hurdles after the 􀀂rst access in clinics and how can corporates and startups work together to accelerate this journey?
Moderator: Malaika Lauk
Speakers:
Christian Kraft, Director Corporate Development – External
Innovation at B. Braun Innovation Hub & Managing Director CeCaVa
GmbH & Co. KG
Dr. Michael Luettgen, Liason Manager at German EIT Health GmbH
Dipl.-Ing. Catherine Schreiber, deputy CEO & COO at ADVITOS
GmbH
16:10 -16:25 Q&A

CLOSING REMARKS: 16:25 – 16:40
16:25 –16:40 Closing remarks